A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
We report the case of a 42-year-old woman with chronic hepatitis C (genotype 1), who in June 2004 started therapy with pegylated interferon alpha (PEG-IFNα) plus ribavirin. Two months later, she discontinued treatment because of polydipsia, polyuria and vomiting leading to a marked dehydration. Biochemical data showed type 1 diabetes mellitus with ketoacidosis, and insulin therapy was started. The patient, who before starting PEG-IFN α plus ribavirin therapy tested negative for glutamic acid decarboxylase antibodies (GADAb) and islet cell (ICAb) antibodies, became strongly positive for both autoimmune markers. This case confirms that patients with chronic hepatitis C who do not have baseline markers of pancreatic autoimmunity may develop severe ketoacidosis during treatment with PEG-IFNα, as well as with standard IFNα. In order to avoid this complication, as no guidelines are available and the pancreatic autoimmunity markers are not routinely analysed, we suggest frequent monitoring (e.g., every one to two weeks) of glycaemic values: e.g., every one to two weeks during the first 3 months (when this complication occurs most frequently) and monthly thereafter so as to identify diabetes at an early stage and before the onset of the appearance of severe ketoacidosis, which is life-threatening.
- Recasens M, Aguilera E, Ampurdanes S, Sanchez Tapias JM, Simo O, Casamitjana R, Conget I (2001) Abrupt onset of diabetes during interferon-alpha therapy in patients with chronic hepatitis C. Diabet Med 18:764–767 CrossRef
- Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C (2003) Review article: type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 18:549–558 CrossRef
- Bosi E, Minelli R, Bazzigaluppi E, Salvi M (2001) Fulminant autoimmune type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease? Diabet Med 18:329–332 CrossRef
- Uto H, Matsuoka H, Murata M, Okamoto, T, Miyata Y, Hori T, Ido A, Hirono S, Hayashi K, Tsubouchi H (2000) A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy. Diabetes Res Clin Pract 49:101–106 CrossRef
- Konrad T, Zeuzem S, Vicini P, Toffolo G, Briem D, Lormann J, Hermann G, Berger A, Kusterer K, Teuber G, Cobelli C, Usadel KH (2000) Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon α. Eur J Clin Invest 30:111–121 CrossRef
- Primo Vera J (2004) Pegylated-interferon-induced diabetes mellitus type 1 in two patients with chronic hepatitis C. Gastroenterol Hepatol 27:69 CrossRef
- Jabr FI, Ordinario MM (2003) Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy. Am J Med 115:148–159 CrossRef
- Chen L-K, Chou Y-C, Tsait S-T, Hwang S-J, Lee S-D (2005) Hepatitis C virus infection-related type 1 diabetes mellitus. Diabet Med 22:340–343 CrossRef
- Schories M, Peters T, Rasenack J, Reincke M (2004) Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha. Dtsch Med Wochenschr 129:1120–1124 CrossRef
- Tohda G, Oida K, Higashi S, Hayashi T, Miyamori I (1998) Interferon alfa and development of type 1 diabetes: a case without insulin resistance. Diabetes Care 21:1774 CrossRef
- A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?
Volume 44, Issue 3 , pp 167-169
- Cover Date
- Print ISSN
- Online ISSN
- Springer Milan
- Additional Links
- Type 1 diabetes mellitus
- Chronic hepatitis C
- Industry Sectors